Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Sep 21;10(18):e020682.
doi: 10.1161/JAHA.120.020682. Epub 2021 Sep 3.

Incidence, Predictor, and Clinical Outcomes of Multiple Resheathing With Self-Expanding Valves During Transcatheter Aortic Valve Replacement

Affiliations
Multicenter Study

Incidence, Predictor, and Clinical Outcomes of Multiple Resheathing With Self-Expanding Valves During Transcatheter Aortic Valve Replacement

Fernando L M Bernardi et al. J Am Heart Assoc. .

Abstract

Background No study has evaluated the impact of the additional manipulation demanded by multiple resheathing (MR) in patients undergoing transcatheter aortic valve replacement with repositionable self-expanding valves. Methods and Results This study included a real-world, multicenter registry involving 16 centers from Canada, Germany, Latin America, and Spain. All consecutive patients who underwent transcatheter aortic valve replacement with the Evolut R, Evolut PRO, and Portico valves were included. Patients were divided according to the number of resheathing: no resheathing, single resheathing (SR), and MR. The primary end point was device success. Secondary outcomes included procedural complications, early safety events, and 1-year mortality. In 1026 patients, the proportion who required SR and MR was 23.9% and 9.3%, respectively. MR was predicted by the use of Portico and moderate/severe aortic regurgitation at baseline (both with P<0.01). Patients undergoing MR had less device success (no resheathing=89.9%, SR=89.8%, and MR=80%; P=0.01), driven by more need for a second prosthesis and device embolization. At 30 days, there were no differences in safety events. At 1 year, more deaths occurred with MR (no resheathing=10.5%, SR=8.0%, and MR=18.8%; P=0.014). After adjusting for baseline differences and center experience by annual volume, MR associated with less device success (odds ratio, 0.42; P=0.003) and increased 1-year mortality (hazard ratio, 2.06; P=0.01). When including only the Evolut R/PRO cases (N=837), MR continued to have less device success (P<0.001) and a trend toward increased mortality (P=0.05). Conclusions Repositioning a self-expanding valve is used in a third of patients, being multiple in ≈10%. MR, but not SR, was associated with more device failure and higher 1-year mortality, regardless of the type of valve implanted.

Keywords: aortic valve stenosis; resheathing; self‐expanding valve; transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

Dr Rodés‐Cabau has received institutional research grants from Medtronic (significant), Edwards Lifesciences (significant), and Boston Scientific (significant). Dr Ribeiro has served as proctor for Edwards Lifescience, Medtronic, and Boston Scientific (significant). Dr Nombela‐Franco has served as proctor for Abbott (significant) and has received speaker honoraria from Edwards Lifesciences (modest). Dr Amat Santos is proctor for Boston Scientific (significant) and has received institutional research grants from Medtronic, Abbott, and Boston Scientific (significant). Dr Mangione has served as proctor for Edwards Lifescience and Medtronic (modest). Dr Pessoa de Melo has served as proctor for Medtronic (significant). Dr Tumeleiro has served as proctor for Medtronic (significant). The remaining authors have no disclosures to report.

Figures

Figure 1
Figure 1. Percentage of the need for single resheathing and multiple resheathing in the study, according to the type of transcatheter heart value (THV) implanted (A) and percentage of resheathing required, reported by previous studies for the different types of THV (B).
Figure 2
Figure 2. Comparison of the Kaplan‐Meier cumulative mortality curves at 1 year among the groups.
In pairwise log‐rank comparison, there was a significant difference between no resheathing (NR) vs multiple resheathing (MR) (P=0.02), and between single resheathing (SR) vs MR (P=0.005). No difference was observed between NR vs SR (P=0.3).

Comment in

References

    1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, et al. Transcatheter aortic‐valve replacement with a balloon‐expandable valve in low‐risk patients. N Engl J Med. 2019;380:1695–1705. DOI: 10.1056/NEJMoa1814052. - DOI - PubMed
    1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. Transcatheter aortic‐valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–1607. DOI: 10.1056/NEJMoa1008232. - DOI - PubMed
    1. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, et al. Transcatheter versus surgical aortic‐valve replacement in high‐risk patients. N Engl J Med. 2011;364:2187–2198. DOI: 10.1056/NEJMoa1103510. - DOI - PubMed
    1. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, Adams DH, Deeb GM, Maini B, Gada H, et al. Surgical or transcatheter aortic‐valve replacement in intermediate‐risk patients. N Engl J Med. 2017;376:1321–1331. DOI: 10.1056/NEJMoa1700456. - DOI - PubMed
    1. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, Gleason TG, Buchbinder M, Hermiller J, Kleiman NS, et al. Transcatheter aortic‐valve replacement with a self‐expanding prosthesis. N Engl J Med. 2014;370:1790–1798. DOI: 10.1056/NEJMoa1400590. - DOI - PubMed

Publication types